KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oscar Health (OSCR) Long-Term Investments (2020 - 2025)

Oscar Health's Long-Term Investments history spans 6 years, with the latest figure at $2.7 billion for Q4 2025.

  • For Q4 2025, Long-Term Investments rose 48.05% year-over-year to $2.7 billion; the TTM value through Dec 2025 reached $2.7 billion, up 48.05%, while the annual FY2025 figure was $2.7 billion, 48.05% up from the prior year.
  • Long-Term Investments reached $2.7 billion in Q4 2025 per OSCR's latest filing, up from $27.9 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $2.8 billion in Q2 2025 to a low of $26.4 million in Q1 2021.
  • Average Long-Term Investments over 5 years is $659.0 million, with a median of $109.9 million recorded in 2023.
  • Peak YoY movement for Long-Term Investments: plummeted 91.38% in 2021, then soared 5977.18% in 2024.
  • A 5-year view of Long-Term Investments shows it stood at $28.1 million in 2021, then decreased by 2.14% to $27.5 million in 2022, then grew by 8.69% to $29.9 million in 2023, then skyrocketed by 5977.18% to $1.8 billion in 2024, then surged by 48.05% to $2.7 billion in 2025.
  • Per Business Quant, the three most recent readings for OSCR's Long-Term Investments are $2.7 billion (Q4 2025), $27.9 million (Q3 2025), and $2.8 billion (Q2 2025).